Skip to main content Accessibility help
×
Home
Hostname: page-component-99c86f546-swqlm Total loading time: 0.886 Render date: 2021-12-02T08:39:10.843Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

Chapter 15 - Cardiovascular Disease and the Menopause

Published online by Cambridge University Press:  18 June 2020

Nicholas Panay
Affiliation:
Queen Charlotte's & Chelsea Hospital, London
Paula Briggs
Affiliation:
Liverpool Women's NHS Foundation Trust
Gabor T. Kovacs
Affiliation:
Monash University, Victoria
Get access

Summary

The age of the natural menopause among women in developed countries is between 50 and 52 years [1, 2] whereas, in the less developed countries, it is 3–4 years less [3]. Deprivation of sex steroid hormones is an important consequence of normal aging and gonadal failure that potentially increases vulnerability to disease in hormone-responsive tissues, including the brain, bone and the cardiovascular system. After menopause, several chronic diseases may emerge, usually by the sixth decade, and these include obesity and metabolic disease, CVD, osteoporosis and arthritis, dementia and cognitive decline, cancer [4]. Obesity is a growing worldwide problem, which exacerbates several chronic diseases. In menopausal women, the incidence of insulin resistance and diabetes has risen exponentially: this translates into an increased risk of CVD and death. If estrogen deprivation leads to altered fat distribution, MHT appears to decrease the incidence of diabetes and also improves diabetes control as indicated by assessment of glycosylated hemoglobin concentrations [5]. CVD is the most common cause of death in women over the age of 50 years. The overall prevalence of coronary heart disease (CHD) is estimated to be 5.1 per cent in women compared with 7.9 per cent in men, and the lifetime risk of developing CHD after 40 years of age is 32 per cent in women and 49 per cent in men; in addition, the incidence of CHD in women lags behind men by 10 years for CHD overall and by 20 years for myocardial infarction (MI) and sudden death. Prior studies have investigated the relationship between menopause and CVD [6]; however, the results have been inconsistent, and the direct causal relationship between menopause and increased cardiovascular risk is still being debated [7]. Major primary prevention measures are smoking cessation, weight loss, blood pressure reduction, regular aerobic exercise and diabetes and lipid control. Primary prevention strategies which are effective in men (use of aspirin and statins) do not afford a protective effect for coronary disease, cardiovascular mortality or all-cause mortality in women [4]. MHT has the potential for improving the cardiovascular risk profile through its beneficial effects on vascular function, lipid levels and glucose metabolism.

Type
Chapter
Information
Managing the Menopause , pp. 144 - 154
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gold, EB, Bromberger, J, Crawford, S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865–74.CrossRefGoogle Scholar
Dratva, J, Gomez, RF, Schindler, C. Is age at menopause increasing across Europe? Results on age at menopause and determinants from two population-based studies. Menopause 2009;16:385–94.Google ScholarPubMed
Kriplani, A, Banerjee, K. An overview of age of onset of menopause in northern India. Maturitas 2005;52:199204.CrossRefGoogle ScholarPubMed
Lobo, RA, Davis, SR, De Villiers, TJ, Gompel, A, Henderson, VW, Hodis, HN, et al. Prevention of diseases after menopause. Climateric 2014;17:117.CrossRefGoogle ScholarPubMed
Manson, JE, Chlebowski, RT, Stefanick, ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68.CrossRefGoogle ScholarPubMed
Wellons, M, Ouyang, P, Schreiner, PJ, Herrington, DM, Vaidya, D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 2012;19:10817.CrossRefGoogle ScholarPubMed
Tom, SE, Cooper, R, Wallace, RB, Guralnik, JM. Type and timing of menopause and later life mortality among women in the Iowa Established Populations for the Epidemiological Study of the Elderly (EPESE) cohort. J Womens Health (Larchmt) 2012;21:1011.CrossRefGoogle ScholarPubMed
Mendelsohn, ME, Karas, RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340(23):1801–11.CrossRefGoogle ScholarPubMed
Fu, XD, Simoncini, T. Non-genomic sex steroid actions in the vascular system. Semin Reprod Med 2007;25(3):178–86.CrossRefGoogle ScholarPubMed
Simoncini, T, Genazzani, AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003;148(3):281–92.Google ScholarPubMed
Simoncini, T, Mannella, P, Fornari, L, Caruso, A, Varone, G, Genazzani, AR. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 2004;69(8–9):537–42.CrossRefGoogle ScholarPubMed
Saito, T, Ciobotaru, A, Bopassa, JC, Toro, L, Stefani, E, Eghbali, M. Estrogen contributes to gender differences in mouse ventricular repolarization. Circ Res 2009;105:343–52.CrossRefGoogle ScholarPubMed
Lagranha, CJ, Deschamps, A, Aponte, A, Steenbergen, C, Murphy, E. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res 2010;106:1681–91.CrossRefGoogle ScholarPubMed
Razmara, A, Duckles, SP, Krause, DN, Procaccio, V. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. Brain Res 2007;1176:7181.CrossRefGoogle ScholarPubMed
Sader, MA, Celermajer, DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res 2002;53:597604.CrossRefGoogle ScholarPubMed
Simoncini, T, Hafezi-Moghadam, A, Brazil, DP, Ley, K, Chin, WW, Liao, JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538–41.CrossRefGoogle ScholarPubMed
Nathan, L, Pervin, S, Singh, R, Rosenfeld, M, Chaudhuri, G. Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: possible mechanisms for gender differences in atherosclerosis. Circ Res 1999;85:377–85.CrossRefGoogle ScholarPubMed
Simoncini, T, Garibaldi, S, Fu, XD, Pisaneschi, S, Begliuomini, S, Baldacci, C, Lenzi, E, Goglia, L, Giretti, MS, Genazzani, AR. Effects of phytoestrogens derived from red clover on atherogenic adhesion molecules in human endothelial cells. Menopause 2008;15:542–50.Google ScholarPubMed
Strehlow, K, Rotter, S, Wassmann, S, Adam, O, Grohe, C, Laufs, K, Böhm, M, Nickenig, G. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003;93:170–7.CrossRefGoogle ScholarPubMed
Signorelli, SS, Neri, S, Sciacchitano, S, Pino, LD, Costa, MP, Pennisi, G, Ierna, D, Caschetto, S. Duration of menopause and behavior of malondialdehyde, lipids, lipoproteins and carotid wall artery intima-media thickness. Maturitas 2001;39:3942.CrossRefGoogle ScholarPubMed
Favre, J, Gao, J, Henry, JP, Remy-Jouet, I, Fourquaux, I, Billon-Gales, A, Thuillez, C, Arnal, JF, Lenfant, F, Richard, V. Endothelial estrogen receptor {alpha} plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/reperfusion. Arterioscler Thromb Vasc Biol 2010;30:2562–7.CrossRefGoogle ScholarPubMed
Hamada, H, Kim, MK, Iwakura, A, Ii, M, Thorne, T, Qin, G, et al. Estrogen receptors alpha and beta mediate contribution of bone marrow–derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation 2006;114:2261–70.CrossRefGoogle ScholarPubMed
Corcoran, MP, Meydani, M, Lichtenstein, AH, Schaefer, EJ, Dillard, A, Lamon-Fava, S. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol 2010;206:217–24.CrossRefGoogle ScholarPubMed
Mayr, M, Niederseer, D, Niebauer, J. From bench to bedside: what physicians need to know about endothelial progenitor cells. Am J Med 2011;124:489.Google ScholarPubMed
Strehlow, K, Werner, N, Berweiler, J, Link, A, Dirnagl, U, Priller, J, Laufs, K, Ghaeni, L, Milosevic, M, Böhm, M, Nickenig, G. Estrogen increases bone marrow–derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003;107:3059–65.CrossRefGoogle ScholarPubMed
Hu, G, Tuomilehto, J, Silventoinen, K, Barengo, N, Jousilahti, P. Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged Finnish men and women. Eur Heart J 2004;25:2212–9.CrossRefGoogle ScholarPubMed
Steinberg, HO, Paradisi, G, Cronin, J, Crowde, K, Hempfling, A, Hook, G, Baron, AD. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 2000;101:2040–6.CrossRefGoogle ScholarPubMed
Reckelhoff, JF, Fortepiani, LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004;43:918–23.CrossRefGoogle ScholarPubMed
Collins, P, Rosano, G, Casey, C, Daly, C, Gambacciani, M, Hadji, P, Kaaja, R, Mikkola, T, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 2007;28:2028–40.CrossRefGoogle ScholarPubMed
Krattenmacher, R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:2938.CrossRefGoogle ScholarPubMed
Archer, DF, Thorneycroft, IH, Foegh, M, Hanes, V, Glant, MD, Bitterman, P, Kempson, RL. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716–27.Google ScholarPubMed
Lerner, DJ, Kannel, WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111:383–90.CrossRefGoogle ScholarPubMed
Grundy, SM, Brewer, HB Jr, Cleeman, JI, Smith, SC Jr, Lenfant, C. Definition of metabolic syndrome: Report of the National Heart, Lung, and BloodInstitute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–8.Google Scholar
Hodis, HN, Mack, WJ. The timing hypothesis: a paradigm shift in the primary prevention of coronary heart disease in women: part 1, comparison of therapeutic efficacy. J Am Geriatr Soc 2013 June;61(6):1005–10.Google ScholarPubMed
Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117(12):1038–41.Google Scholar
Ghazal, S, Pal, L. Perspective on hormone therapy 10 years after the WHI. Maturitas 2013;76(3):208–12.CrossRefGoogle ScholarPubMed
Hodis, HN, Mack, WJ. A ‘window of opportunity’: the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res 2011;1379:244–52.CrossRefGoogle Scholar
Baber, RJ, Panay, N, Fenton, A, IMS Writing Group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climateric 2016;19(2):109–50.CrossRefGoogle ScholarPubMed
Boardman, HM, Hartley, L, Eisinga, A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;3:CD002229.Google Scholar
Miller, VM, Naftolin, F, Asthana, S, Black, DM, Brinton, EA, Budoff, MJ, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause 2019 Sep;26:1071–84.CrossRefGoogle Scholar
Hodis, HN, Mack, HJ, Henderson, WV, Shoupe, D, Budoff, MJ, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31.CrossRefGoogle ScholarPubMed
Harman, SM, Black, DM, Naftolin, F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60.CrossRefGoogle ScholarPubMed
Schierbeck, LL, Rejnmark, L, Tofteng, CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012;345:e6409.CrossRefGoogle Scholar
Hormone therapy and heart disease. Obstet Gynecol 2013;121:1407–10.Google Scholar
Williams, B, Mancia, G, Spiering, W, Rosei, EA, Azizi, M, Burnier, M, et al. ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021–104.CrossRefGoogle ScholarPubMed
The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017;24(7):728–75.Google Scholar

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×